Clinical Trial Update: Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update investigates dose escalation for patients with ADHD who do not respond to standard atomoxetine doses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED